Lucentis Injection Should Be Given To Wet AMD Patients, Says NICE, UK

Editor's Choice
Main Category: Eye Health / Blindness
Also Included In: Seniors / Aging
Article Date: 14 Dec 2007 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 and a half stars

4.46 (13 votes)

Healthcare Prof:5 stars

5 (2 votes)

Article Opinions: 1 posts

Patients with wet age-related macular degeneration (Wet AMD) should be eligible for 14 lucentis (ranibizumab) injections per eye, says the National Institute for Health and Clinical Excellence (NICE). This is a complete reversal on its previous recommendation. The new recommendation does not include eligibility for Macugen, another injection.

* Wet age-related macular degeneration is known as Wet ARMD, or Wet AMD

According to NICE, after further economic modeling of available treatments, it decided to modify its recommendation with regard to Lucentis injections.

Wet AMD is the main cause of blindness in the United Kingdom; there are approximately 26,000 new cases annually. Today about 250,000 people are effected with wet AMD in the UK.

In Scotland both Lucentis and Macugen have been widely available on the National Health Service (NHS). Both drugs are known as ant-VEGF drugs - they target a protein that stops damage to the retina.

Initially, NICE had recommended that about 20% of patients with wet AMD would be eligible to receive Lucentis injections on the NHS. This involved patients with a particular type of wet AMD who had both eyes affected - the Lucentis would only be used on the less badly affected eye.

The new recommendation includes patients who only have one eye affected, and not only patients with a particular type of wet AMD. However, treatment on the NHS will only be given to patients after a certain amount of deterioration has passed. If more than 14 injections are needed for a particular patient, the manufacturer of Lucentis will pay for the extra ones.

NICE informs that the final guidance will be published early next year.

Ophthalmologists welcome the news. However, they would like to see Macugen added as a treatment for those who have problems with Lucentis.

-- What is Age-Related Macular Degeneration?
-- www.lucentis.com
-- www.macugen.com
-- www.nice.org.uk

Written by - Christian Nordqvist

View drug information on Lucentis; Macugen.

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our eye health / blindness section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Christian Nordqvist. "Lucentis Injection Should Be Given To Wet AMD Patients, Says NICE, UK." Medical News Today. MediLexicon, Intl., 14 Dec. 2007. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/articles/91761.php>

APA
Christian Nordqvist. (2007, December 14). "Lucentis Injection Should Be Given To Wet AMD Patients, Says NICE, UK." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/articles/91761.php.

Please note: If no author information is provided, the source is cited instead.


Eye Health / Blindness

Most Popular Articles



Follow Our Eye Health News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Eye Health / Blindness Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »